14/09/2018 14:04:14

Global Medical Marijuana (MMJ) Market to witness a CAGR of 19.1% during 2018-2024

NEW YORK, Sept. 14, 2018 (GLOBE NEWSWIRE) -- The global medical marijuana market is expected to grow significantly from USD 8,280.6 million in 2017 to USD 28,070.0 million in 2024, at a CAGR of 19.1% from 2018 to 2024. Factors propelling the growth of medical marijuana market are growing awareness regarding the benefits offered, increasing demand for marijuana in the treatment of various diseases, and growing number of research and development activities. Moreover, several clinical trials are underway which are expected to drive the market demand over the years to come.

The National Institute on Drug Abuse maintains detailed information on the therapeutic as well as abusive aspects of marijuana. National Institutes of Health (NIH) provides funding to the researchers who are involved in exploring the therapeutic uses of medical marijuana. Recent studies have shown that marijuana extracts may kill certain cancer cells and also helps in the cure of epilepsy.

Key findings from the report:

  • The global medical marijuana market is expected to reach USD 28,070.0 million by 2024 at CAGR of 19.1% form 2018-2024

  • Based on application, the chronic pain segment held the major share of the global market in 2017, due to hundreds of chemical compounds found in marijuana which aid in treating pain

  • Sativa type emerged as the largest segment in 2017 and is projected to maintain its dominance over the forecast period, while depicting a healthy CAGR.

  • Based on the chemical derivatives, the CBD (cannabidiol) segment accounted for the largest share of the MMJ market, owing to increasing research and development activities along with the growing demand in application such as capsules, tincture, gum, oil, and personal care products

  • On the basis of end-use, the pharmaceutical industry held the maximum share of the market in 2017. The increasing demand for MMJ from the pharmaceutical industry is due to its usage in developing new drugs for medical treatment of patients

  • The key players operating in the medical marijuana market are Cannabis Sativa, Inc; GB Sciences; GW Pharmaceuticals PLC; United Cannabis Corporation; Corbus Pharmaceuticals; Insys Therapeutics, Inc.; Lexaria Corporation; Canopy Growth Corporation; Aurora Cannabis; AXIM Biotechnologies Inc.; Medical Marijuana, Inc.; Arena Pharmaceuticals; and Cara Therapeutics

  • As of March 2018, GW Pharmaceuticals, announced receipt of Notices of Allowance for five new Epidiolex patent applications to be listed in the approved drug products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) if the NDA for Epidiolex is approved. Once issued, these patents are set to expire in 2035. One or more patents may be eligible for additional patent term through patent term adjustment and/or regulatory exclusivities.

MMJ- offering business opportunity in the medical industry

Medical marijuana plant contains many chemical properties that may help in treating a wide range of diseases and symptoms. The medical marijuana plant having two major strains: cannabis sativa and cannabis indica. The cannabis sativas have a higher level of TCH (delta-9 tetrahydrocannabinol) resulting in a medical application such as control of nausea, vomiting, and stimulate appetite in AIDS patients. The cannabis indica have a higher level of CBD (cannabidiol), resulting in treatment of symptoms such as muscle spasms, chronic pain, anxiety and sleep deprivation. The industry size for medical marijuana is increasing primarily in U.S. offering business opportunity with high profit margins. However, federal prohibition remains to be key restraint to market growth across the globe.

Browse full research report with TOC on “

Global Medical Marijuana Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024

” at:


To purchase report:


Global Medical Marijuana Market – Regional Insight

North America held the largest share of the global medical marijuana market in 2017 and is expected to show high growth rate due to growing number of U.S states, legalizing the use of marijuana in the medical applications. Europe holds the second largest share in the global medical marijuana market in 2017. Growing importance of cannabis sector coupled with several legalization initiatives is likely to augment the market growth in Europe. Additionally, the North America region is expected to witness the fastest CAGR during the period 2018–2024. The aforementioned growth can be attributed to increasing awareness about MMJ along with favorable government legislations for medicinal use of marijuana.

The report segments medical marijuana market on the basis of type, application, chemical derivatives, end use, and region.

By Type

  • Sativa
  • Indica
  • Hybrid

By Application

  • Glaucoma
  • Inflammatory bowel diseases
  • Chronic Pain
  • Migraine

  • Arthritis
  • Anxiety
  • Insomnia
  • AIDS
  • Others
  • By Chemical Derivatives

    • THC
    • CBD
      • CBD Capsules
      • CBD Tinctures
      • CBD Topicals
    • Hybrid

    By End-Use

    • Pharmaceutical industry
    • Research & development centres
    • Others

    By Region

    • North America
    • Europe
    • Asia-Pacific
    • Central & South America (CSA)
    • Middle East & Africa (MEA)

    About Energias Market Research Pvt. Ltd.


    Energias Market Research launched with the objective to provide in-depth market analysis, business research solutions, and consultation that is tailored to our client’s specific needs based on our impeccable research methodology.

    With a wide range of expertise from various industrial sectors and more than 50 industries that include energy, chemical and materials, information communication technology, semiconductor industries, healthcare and daily consumer goods, etc. We strive to provide our clients with a one-stop solution for all research and consulting needs.

    Our comprehensive industry-specific knowledge enables us in creating high quality global research outputs. This wide-range capability differentiates us from our competitors.



    Alan Andrews

    Business Development Manager

    For any queries email us:


    To purchase report:


    Call us: +1-716-239-4915




    Post comment

    Related debate

    • 1 week
    • 1 month
    • 1 Year
    13 Nov
    Hvis jeg må være så fri at komme med en opfordring til de ansvarlige for dette forum. I skulle prøve..
    18 Nov
    For de der ikke har set det, er der en aktuel artikel i Medwatch hvor Craig Collard udtaler sig. D..
    Der er mange gode bidrag i debatten - og mange der ikke har brugt 5 minutter på at sætte sig ind i h..
    14 Nov
    Jeg har det lidt som vagabonderne Vladimir og Estragon i Samuel Becketts skuespil,hvor de 2 sidder u..
    16 Nov
    Jeg er ikke klogere end andre, hvorfor årsag til fald vil være en gisning - det vil jeg afholde mig ..
    16 Nov
    Kære NKT, Bestyrelse og direktion   Jeg vil gerne hører om I selv foranlediger en undersøgelse af om..
    15 Nov
    Lidt tanker omkring Velos prissætning og hvorfor jeg stadig finder den absurd undervurderet: De h..
    16 Nov
    @nystart Jeg er ikke uenig med dig, men jeg tror, at du har valgt den forkerte dag at vaere bedrevid..
    14 Nov
    Faktisk har der været meget stille herinde mht Genmab i rigtig lang tid. Efter at GW fik skræmt alle..
    16 Nov
    ...og hvis man lige skal kaste et kort blik på forretningen Vestas, særligt i forhold til markedet, ..

    HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

    22/02/2018 10:54:53
    FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

    Rathbone Brothers Plc : Preliminary announcement of 2017 results

    22/02/2018 07:00:19
    Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

    Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

    Related news
    21/02/2018 15:25:10
    FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

    Most read news

    • 24 hours
    • 48 hours
    • 1 week
    Kirkland Lake Gold Announces Management Changes
    STOCKHOLDER ALERT: Kaskela Law LLC Announces Stockholder Class Action Against Alphabet, Inc. and Encourages Investors to Contact the Firm – GOOG
    Adacel to Feature Support Services at I/ITSEC 2018
    ITRI Receives Three 2018 R&D 100 Awards
    Identity verification may reduce cost of compliance by up to 70% for digital lenders

    Buy and sell signals

    • Trend
    • Moneymachine

    Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
    Quote information is delivered by Morningstar.
    Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
    19 November 2018 20:34:35
    (UTC+00:00) Dublin, Edinburgh, Lisbon, London
    Version: LiveBranchBuild_20181114.1 - EUROWEB3 - 2018-11-19 21:34:35 - 2018-11-19 20:34:35 - 1000 - Website: OKAY